Abstract 285P
Background
Adjuvant ET reduces breast cancer recurrence and increases overall survival among patients with early-stage ER+ breast cancer, however a suboptimal number of patients older than 65 years are included in the studies. This study aims to evaluate adherence to adjuvant ET and sexual dysfunction in women >65 years old with early breast cancer.
Methods
Women with a history of early-stage ER+ invasive carcinoma of the breast on adjuvant ET for at least 6 months were invited to participate. Adherence was assessed with Morisky Medication Adherence Scale (MMAS-8). Quality of life was assessed using EORTC QLQ C30 and BR-23 forms. Sexuality was assessed with the Female Sex Function Index questionnaire. Patients were stratified according to age <=65 years and > 65 years old. Qualitative variables were compared between groups using the Chi-square or exact Chi-square test and for quantitative variables the non-parametric Mann-Whitney test was used.
Results
From June 2021 to March 2024, 774 women from 15 Brazilian institutions were recruited. Mean age was 62 y.o, mean tumor size was 2.24 cm, mean duration of ET was 3.2y. About 191 patients (24.7%) were older than 65y, 69.6% of them were high adherent to ET and 70.7% had sexual dysfunction. In comparison with women <=65 y.o, older women were associated with private healthcare insurance (p=0.003), living with no partner (p < 0.0001), prior lumpectomy (p = 0.0017), prior sentinel node biopsy (p = 0.03), no prior chemotherapy (p < 0.0001), use of aromatase inhibitors (p < 0.0001) and use of concomitant medications (p < 0,0001). Patients older than 65 years were more associated with lower adherence (p = 0.0009), but there was no difference in sexual dysfunction in comparison with patients less than 65 y. Patients over 65 years had significantly higher scores for Emotional Functioning, Cognitive Functioning, Social Functioning, Body Image and Future Perspective domains of quality of life.
Conclusions
Patients older than 65 y.o had less aggressive treatments, many better domains in quality of life, but lower adherence to ET than patients aged up to 65 years. An important issue for womens’ health is sexual health and in this context, sexual dysfunction affects women besides age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
334P - Cardiovascular events related to CDK4/6 inhibitors: A systematic review and safety meta-analysis of randomized controlled trials
Presenter: Louis Boismoreau
Session: Poster session 14
335P - First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 14
336P - Determination of the most common hereditary mutations associated with breast cancer and ovarian cancer in the population of Ukrainian women
Presenter: Dmytro Nehrulia
Session: Poster session 14
337P - Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?
Presenter: Jennifer Chen
Session: Poster session 14
338TiP - EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Presenter: Michail Ignatiadis
Session: Poster session 14
339TiP - A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Presenter: Theodoros Foukakis
Session: Poster session 14
351P - Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial
Presenter: Giampaolo Bianchini
Session: Poster session 14
352P - Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)
Presenter: Noor Wortelboer
Session: Poster session 14
353P - Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Presenter: Robert Scheel
Session: Poster session 14